Children whose mothers used tenofovir-based pre-exposure prophylaxis (PrEP) during pregnancy did not have reduced bone density or stunted growth as compared with unexposed infants, according to study findings presented at the 12th International AIDS Society Conference on HIV Science (IAS 2023).
“Our findings bolstered the safety profile of PrEP use for pregnant women,” presenter Dr. Linxuan Wu of the University of Washington in Seattle and colleagues concluded.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.